Tirzepatide
Dual-action GLP-1 / GIP for greater metabolic impact.
What it is
A once-weekly dual GLP-1 / GIP medication that acts on two metabolic pathways at once.
Who it’s for
Adults seeking greater metabolic impact than a single-pathway GLP-1, under close provider guidance.
How it works
By engaging both GLP-1 and GIP receptors it curbs appetite and improves how your body handles glucose and fat. Dosing is stepped up slowly.
What to expect
Often more pronounced weight and metabolic changes, with the same emphasis on monitoring and sustainable habits.
Anyone can sell you the prescription. Almost nobody watches what it does.
The prescription is the cheap half. The expensive half is knowing whether it worked, catching what it moved, and changing it when the numbers say so.
We make our money on the membership. Not on your medication.
Membership
$38.50/mo
Clinician, record, unlimited messages, and every protocol change.
Or $360 for the year, with your 160+ biomarker panel included.
Medication
Cost plus a markup confirmed at launch
Compounded and shipped from a US-licensed pharmacy.
Panels
Confirmed at launch
Baseline before you start, then monitoring every quarter.
The basics, answered.
Is this covered by insurance?
Prime Years is cash-pay by design: no claims and no prior authorizations. You get transparent pricing and faster access.
How do I get started?
Complete the online intake. A licensed provider reviews your goals, history, and labs, then designs a protocol if you’re a fit.
How is my progress tracked?
Your biomarkers and symptoms are monitored over time in your PYM Analysis dashboard, so your protocol can be fine-tuned.
Find out whether you actually need this.
Bring a panel from any lab in the country and your Prime Score is read from it. Enrollment is not open yet, so this starts with the waitlist.
This page is illustrative and pre-launch. Tirzepatide is described in general terms; eligibility, dosing and outcomes are determined by a licensed clinician based on your evaluation. Final product and medical copy pending clinical and legal review.